Cargando…

Distinct mechanistic activity profile of pralatrexate in comparison to other antifolates in in vitro and in vivo models of human cancers

PURPOSE: This study evaluated mechanistic differences of pralatrexate, methotrexate, and pemetrexed. METHODS: Inhibition of dihydrofolate reductase (DHFR) was quantified using recombinant human DHFR. Cellular uptake and folylpolyglutamate synthetase (FPGS) activity were determined using radiolabeled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izbicka, E., Diaz, A., Streeper, R., Wick, M., Campos, D., Steffen, R., Saunders, M.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2009
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728224/ https://www.ncbi.nlm.nih.gov/pubmed/19221750 http://dx.doi.org/10.1007/s00280-009-0954-4

Ejemplares similares

Cancer drug development yesterday, today and tomorrow
por: Izbicka, Elzbieta, et al.
Publicado: (2023)

Mitigation of Insulin Resistance by Natural Products from a New Class of Molecules, Membrane-Active Immunomodulators
por: Izbicka, Elzbieta, et al.
Publicado: (2023)

Structure-Guided In Vitro to In Vivo Pharmacokinetic Optimization of Propargyl-Linked Antifolates
por: Lombardo, M.N., et al.
Publicado: (2019)

Single agent and combination studies of pralatrexate and molecular correlates of sensitivity
por: Serova, M, et al.
Publicado: (2011)

Pralatrexate for refractory mycosis fungoides in two Japanese patients
por: Teraishi, Mika, et al.
Publicado: (2021)

Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma
por: Bhangoo, Ronik S., et al.
Publicado: (2018)

Critical appraisal of pralatrexate in the management of difficult-to-treat peripheral T cell lymphoma
por: Casanova, M, et al.
Publicado: (2011)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Relapsed refractory nodal peripheral T-cell lymphoma with follicular helper T-cell phenotype was initially resistant to pralatrexate and confirmed to be unresponsive to subsequent forodesine, but responded to re-instituted pralatrexate
por: Sekiguchi, Yasunobu, et al.
Publicado: (2020)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
por: Rodd, Annabelle L., et al.
Publicado: (2012)

Characterization of newly established Pralatrexate-resistant cell lines and the mechanisms of resistance
por: Oiwa, Kana, et al.
Publicado: (2021)

Chiral evasion and stereospecific antifolate resistance in Staphylococcus aureus
por: Wang, Siyu, et al.
Publicado: (2022)

Antifolate Agents Against Wild and Mutant Strains of Plasmodium falciparum
por: Shaikh, M. S., et al.
Publicado: (2014)

Preclinical evaluation of the anti-tumor activity of pralatrexate in high-risk neuroblastoma cells
por: Clark, Rachael A., et al.
Publicado: (2020)

Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors
por: Wróbel, Agnieszka, et al.
Publicado: (2019)

Leucovorin rescue allows effective high-dose pralatrexate treatment and an increase in therapeutic index in mesothelioma xenografts
por: Tedeschi, Philip M., et al.
Publicado: (2014)

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination
por: Tedeschi, Philip M., et al.
Publicado: (2015)

Transgenic Plasmodium parasites stably expressing Plasmodium vivax dihydrofolate reductase-thymidylate synthase as in vitro and in vivo models for antifolate screening
por: Somsak, Voravuth, et al.
Publicado: (2011)

Prevalence of antifolate resistance mutations in Plasmodium falciparum isolates in Afghanistan
por: Awab, Ghulam R, et al.
Publicado: (2013)

Clinical efficacy and mechanism of Pralatrexate combined with Palbociclib Isethionate in treatment of bladder cancer patients
por: Wang, Xiaobin, et al.
Publicado: (2019)

Pralatrexate for Prolonged Treatment of Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, with Prophylactic Leucovorin
por: Kitazume, Koichi, et al.
Publicado: (2019)

Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients
por: Lee, Seung-Shin, et al.
Publicado: (2016)

Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis
por: Hong, Jung Yong, et al.
Publicado: (2019)

First-in-class multifunctional TYMS nonclassical antifolate inhibitor with potent in vivo activity that prolongs survival
por: Guijarro, Maria V., et al.
Publicado: (2023)

Schedule-Dependent Synergy Between the Histone Deacetylase Inhibitor Belinostat and the Dihydrofolate Reductase Inhibitor Pralatrexate in T-and B-cell Lymphoma Cells in vitro
por: Peters, Godefridus J., et al.
Publicado: (2020)

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T‐cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2017)

Polymorphisms in Plasmodium vivax antifolate resistance markers in Afghanistan between 2007 and 2017
por: Rakmark, Kasama, et al.
Publicado: (2020)

The Impact of Short-Term, Intensive Antifolate Treatment (with Pyrimethamine and Sulfadoxine) and Antibiotics Followed by Long-Term, Secondary Antifolate Prophylaxis on the Rate of Toxoplasmic Retinochoroiditis Recurrence
por: Borkowski, Piotr K., et al.
Publicado: (2016)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment
por: Merdin, Alparslan, et al.
Publicado: (2019)

The Role of Folate Transport in Antifolate Drug Action in Trypanosoma brucei
por: Dewar, Simon, et al.
Publicado: (2016)

Factors Influencing the Antifolate Activity of Synthetic Tea-Derived Catechins
por: Sáez-Ayala, Magalí, et al.
Publicado: (2013)

Folate transporter dynamics and therapy with classic and tumor-targeted antifolates
por: O’Connor, Carrie, et al.
Publicado: (2021)

Effects of Metformin Combined With Antifolates on HepG2 Cell Metabolism and Cellular Proliferation
por: Tawfik, Sherouk M., et al.
Publicado: (2022)

A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro
por: Zhang, Haiping, et al.
Publicado: (2020)

Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study
por: Hong, Xiaonan, et al.
Publicado: (2019)

Submicroscopic Gametocytes and the Transmission of Antifolate-Resistant Plasmodium falciparum in Western Kenya
por: Oesterholt, Mayke J. A. M., et al.
Publicado: (2009)

Propargyl-Linked Antifolates are Dual Inhibitors of Candida albicans and Candida glabrata
por: G-Dayanandan, Narendran, et al.
Publicado: (2014)

Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment: Erratum
Publicado: (2020)

Independent Origin of Plasmodium falciparum Antifolate Super-Resistance, Uganda, Tanzania, and Ethiopia
por: Alifrangis, Michael, et al.
Publicado: (2014)

Multimodality Imaging Identifies Distinct Metabolic Profiles In Vitro and In Vivo()
por: Neveu, Marie-Aline, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_m1fsvo54dctioji0l2ln0n8g9k